{
    "clinical_study": {
        "@rank": "100655", 
        "arm_group": {
            "arm_group_label": "TA-650", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650\n      at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom  effect of\n      the treatment was confirmed after the treatment with Remicade\u00ae at 5 mg/kg every 8 weeks but\n      decreased thereafter."
        }, 
        "brief_title": "A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Plaque Psoriasis", 
            "Psoriatic Arthritis", 
            "Pustular Psoriasis (Excluding a Localized)", 
            "Psoriatic Erythroderma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic", 
                "Dermatitis, Exfoliative", 
                "Psoriasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Patients with plaque psoriasis or psoriatic arthritis:\n\n             1. Screening Period:\n\n                TA-650 at 5 mg per kg body weight is administered on the day of TA-650\n                administration at the start (week 0) and week 8 (if efficacy is not judged as\n                decreased or maintained at week 8 of the screening period) , respectively, by\n                intravenous infusion slowly over at least 2 hours.\n\n             2. Increased Dose Period:\n\n                If efficacy is judged as decreased in the screening period, TA-650 at 10 mg per kg\n                body weight is administered on the day of TA-650 administration at the start (week\n                0) and at every 8 weeks up to week 32 in the increased dose period , respectively,\n                as one dose by intravenous infusion slowly over at least 2 hours.\n\n        -  Patients with pustular psoriasis or psoriatic erythroderma:\n\n      TA-650 at 10 mg per kg body weight is administered on the day of TA-650 administration at\n      the start (week 0) and at every 8 weeks up to week 32, respectively, as one dose by\n      intravenous infusion slowly over at least 2 hours."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have already been diagnosed as having plaque psoriasis, psoriatic\n             arthritis, pustular psoriasis (excluding a localized), or psoriatic erythroderma.\n\n          -  Patients in whom effect of the treatment was confirmed for a certain period after the\n             start of administration of Remicade\u00ae at 5 mg/kg at every 8 weeks but decreased\n             thereafter.\n\n        Exclusion Criteria:\n\n          -  Patients who have guttate psoriasis.\n\n          -  Patients who have drug-induced psoriasis\n\n          -  Patients who have previously used any other  biological products than infliximab.\n\n          -  Patients who have a concomitant diagnosis, or a history within 6 months prior to\n             provisional enrollment, of serious infections that need hospitalization.\n\n          -  Patients who have a concomitant diagnosis, or a history within 6 months prior to\n             provisional enrollment, of opportunistic infections\n\n          -  Female patients who are pregnant, breast-feeding, or possibly pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680159", 
            "org_study_id": "TA-650-24"
        }, 
        "intervention": {
            "arm_group_label": "TA-650", 
            "intervention_name": "TA-650", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Infliximab", 
            "REMICADE", 
            "TA-650", 
            "psoriasis"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kinki", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tohoku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "overall_official": [
            {
                "affiliation": "Social Insurance Central General Hospital", 
                "last_name": "Hideshi Torii, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Mitsubihsi Tanabe Pharma Corporation", 
                "last_name": "Kazuoki Kondo, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "The Jikei University School of Medicine", 
                "last_name": "Hidemi Nakagawa, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients achieving 75% improvement in the Psoriasis Area and Severity Index (PASI) score", 
            "safety_issue": "No", 
            "time_frame": "Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 in Increased Dose Period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PASI score", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 in Increased Dose Period"
            }, 
            {
                "measure": "Physician Global Assessment (PGA) for skin lesions (Only for patients with plaque psoriasis)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 in Increased Dose Period"
            }, 
            {
                "measure": "Visual Analog Scale\uff08VAS\uff09 of pain assessment by subjects (Only for patients with psoriatic arthritis)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 in Increased Dose Period"
            }, 
            {
                "measure": "Assessment of severity (Only for patients with pustular psoriasis)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 in Increased Dose Period"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}